Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Focal receives U.S. approval

The FDA granted marketing approval for FOCL's FocalSeal-L synthetic

Read the full 94 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE